← Oncology Approval Tracker

FDA DECISION ·

Inlyta + avelumab or pembrolizumab

axitinib + avelumab or pembrolizumab · Pfizer

FDA approvalNew or expanded indicationRenal cell carcinoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

First-line treatment of advanced renal cell carcinoma in combination with either avelumab or pembrolizumab, added to the axitinib label.

LAMPGEN ANALYSIS

Why it matters

Aligned axitinib’s own prescribing information with two combination regimens authorized on the immunotherapy labels in 2019.

What research teams should watch

Avoid double-counting the regimen’s initial 2019 approvals when comparing historical action totals.

PRIMARY RECORDS

Sources